Identification

Name
Gabapentin Enacarbil
Accession Number
DB08872  (DB04922)
Type
Small Molecule
Groups
Approved
Description

Gabapentin enacarbil is marketed under the name Horizant. It is a prodrug of gabapentin, and indicated in adults for the treatment of Restless Legs Syndrome (RLS) and postherpetic neuralgia (PHN).

Structure
Thumb
Synonyms
  • Gabapentina enacarbilo
  • Gabapentine enacarbil
  • Gabapentinum enacarbilum
External IDs
ASP-8825 / ASP8825 / GSK-1838262 / GSK1838262 / XP 13512 / XP-13512 / XP13512
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
HorizantTablet, extended release300 mg/1OralRemedy Repack2016-09-02Not applicableUs
HorizantTablet, extended release300 mg/1OralArbor Pharmaceuticals2013-05-01Not applicableUs
HorizantTablet, extended release600 mg/1OralArbor Pharmaceuticals2013-05-01Not applicableUs53451 0101 01 nlmimage10 e73b73eb
Categories
UNII
75OCL1SPBQ
CAS number
478296-72-9
Weight
Average: 329.393
Monoisotopic: 329.183837593
Chemical Formula
C16H27NO6
InChI Key
TZDUHAJSIBHXDL-UHFFFAOYSA-N
InChI
InChI=1S/C16H27NO6/c1-11(2)14(20)22-12(3)23-15(21)17-10-16(9-13(18)19)7-5-4-6-8-16/h11-12H,4-10H2,1-3H3,(H,17,21)(H,18,19)
IUPAC Name
2-(1-{[({1-[(2-methylpropanoyl)oxy]ethoxy}carbonyl)amino]methyl}cyclohexyl)acetic acid
SMILES
CC(C)C(=O)OC(C)OC(=O)NCC1(CC(O)=O)CCCCC1

Pharmacology

Indication

For the treatment of adult Restless Legs Syndrome (RLS) and postherpetic neuralgia (PHN).

Structured Indications
Pharmacodynamics

Since gabapentin enacarbil is a prodrug of gabapentin, it's physiological effects are the same as gabapentin. Concerning PHN, gabapentin prevents allodynia and hyperalgesia.

Mechanism of action

Although the exact mechanism of action of gabapentin in RLS and PHN is unknown, it is presumed to involve the descending noradrenergic system, resulting in the activation of spinal alpha2-adrenergic receptors.

TargetActionsOrganism
UVoltage-dependent calcium channel subunit alpha-2/delta-1Not AvailableHuman
UVoltage-dependent calcium channel subunit alpha-2/delta-2Not AvailableHuman
Absorption

Gabapentin enacarbil is absorbed in the intestines by active transport through the proton-linked monocarboxylate transporter, MCT-1.

Volume of distribution

The volume of distribution is 76L.

Protein binding

Gabapentin plasma protein binding is less than 3%.

Metabolism

Gabapentin enacarbil does not interact with any of the major cytochrome P450 enzymes.

Route of elimination

Gabapentin enacarbil is eliminated primarily in the urine (94%) and to a lesser extent in the feces (5%).

Half life

The elimination half-life of gabapentin is 5.1 to 6.0 hours.

Clearance

Renal clearance of gabapentin is 5 to 7 L/hr.

Toxicity

Most common adverse reactions are headache, dizziness, and somnolence.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Gabapentin Enacarbil.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Gabapentin Enacarbil.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Gabapentin Enacarbil.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Adipiplon is combined with Gabapentin Enacarbil.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Gabapentin Enacarbil.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Gabapentin Enacarbil.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Gabapentin Enacarbil.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Allopregnanolone is combined with Gabapentin Enacarbil.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Gabapentin Enacarbil.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Gabapentin Enacarbil.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Gabapentin Enacarbil.Approved, Illicit, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Gabapentin Enacarbil.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Gabapentin Enacarbil.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Gabapentin Enacarbil.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Gabapentin Enacarbil.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Gabapentin Enacarbil.Experimental
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Gabapentin Enacarbil.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Gabapentin Enacarbil.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Gabapentin Enacarbil.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Gabapentin Enacarbil.Investigational, Vet Approved
AzelastineGabapentin Enacarbil may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Gabapentin Enacarbil.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Gabapentin Enacarbil.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Benperidol is combined with Gabapentin Enacarbil.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Gabapentin Enacarbil.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Gabapentin Enacarbil.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Gabapentin Enacarbil.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Gabapentin Enacarbil.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Bromisoval is combined with Gabapentin Enacarbil.Experimental
BromperidolThe risk or severity of adverse effects can be increased when Bromperidol is combined with Gabapentin Enacarbil.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Gabapentin Enacarbil.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Gabapentin Enacarbil.Approved, Investigational, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Gabapentin Enacarbil.Approved, Investigational
BuprenorphineGabapentin Enacarbil may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Gabapentin Enacarbil.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Gabapentin Enacarbil.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Gabapentin Enacarbil.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Gabapentin Enacarbil.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Gabapentin Enacarbil.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Gabapentin Enacarbil.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Gabapentin Enacarbil.Approved, Illicit, Vet Approved
CanertinibThe risk or severity of adverse effects can be increased when Canertinib is combined with Gabapentin Enacarbil.Investigational
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Gabapentin Enacarbil.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Gabapentin Enacarbil.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Gabapentin Enacarbil.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Gabapentin Enacarbil.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Gabapentin Enacarbil.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Gabapentin Enacarbil.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Gabapentin Enacarbil.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Gabapentin Enacarbil.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Gabapentin Enacarbil.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Gabapentin Enacarbil.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Gabapentin Enacarbil.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Gabapentin Enacarbil.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Gabapentin Enacarbil.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Gabapentin Enacarbil.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Gabapentin Enacarbil.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Gabapentin Enacarbil.Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Gabapentin Enacarbil.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Gabapentin Enacarbil.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Gabapentin Enacarbil.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Gabapentin Enacarbil.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Gabapentin Enacarbil.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Clopenthixol is combined with Gabapentin Enacarbil.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Gabapentin Enacarbil.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Clothiapine is combined with Gabapentin Enacarbil.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Gabapentin Enacarbil.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Gabapentin Enacarbil.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Gabapentin Enacarbil.Approved, Illicit
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Gabapentin Enacarbil.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Gabapentin Enacarbil.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Gabapentin Enacarbil.Approved
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Gabapentin Enacarbil.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Gabapentin Enacarbil.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Dapoxetine.Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Deramciclane is combined with Gabapentin Enacarbil.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Gabapentin Enacarbil.Approved
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Gabapentin Enacarbil.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Gabapentin Enacarbil.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Gabapentin Enacarbil.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Gabapentin Enacarbil.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Gabapentin Enacarbil.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Gabapentin Enacarbil.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Gabapentin Enacarbil.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Gabapentin Enacarbil.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Gabapentin Enacarbil.Approved, Illicit, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Diethyl ether is combined with Gabapentin Enacarbil.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Gabapentin Enacarbil.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Gabapentin Enacarbil.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Gabapentin Enacarbil.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Gabapentin Enacarbil.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Gabapentin Enacarbil.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Gabapentin Enacarbil.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Gabapentin Enacarbil.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Dixyrazine is combined with Gabapentin Enacarbil.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Gabapentin Enacarbil.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Gabapentin Enacarbil.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Gabapentin Enacarbil.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Gabapentin Enacarbil.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Gabapentin Enacarbil.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Gabapentin Enacarbil.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Gabapentin Enacarbil.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Gabapentin Enacarbil.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Gabapentin Enacarbil.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Ecopipam is combined with Gabapentin Enacarbil.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Gabapentin Enacarbil.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Eltanolone is combined with Gabapentin Enacarbil.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Gabapentin Enacarbil.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Gabapentin Enacarbil.Approved, Investigational
EscitalopramThe risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Gabapentin Enacarbil.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Gabapentin Enacarbil.Approved
EthanolEthanol may increase the central nervous system depressant (CNS depressant) activities of Gabapentin Enacarbil.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Gabapentin Enacarbil.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Gabapentin Enacarbil.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Gabapentin Enacarbil.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Gabapentin Enacarbil.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Ethyl chloride is combined with Gabapentin Enacarbil.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Gabapentin Enacarbil.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Gabapentin Enacarbil.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Gabapentin Enacarbil.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Gabapentin Enacarbil.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Gabapentin Enacarbil.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Gabapentin Enacarbil.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Gabapentin Enacarbil.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Ezogabine is combined with Gabapentin Enacarbil.Approved
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Gabapentin Enacarbil.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Gabapentin Enacarbil.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Gabapentin Enacarbil.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Gabapentin Enacarbil.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Gabapentin Enacarbil.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Fluanisone is combined with Gabapentin Enacarbil.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Gabapentin Enacarbil.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Gabapentin Enacarbil.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Gabapentin Enacarbil.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Gabapentin Enacarbil.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Gabapentin Enacarbil.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Gabapentin Enacarbil.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Gabapentin Enacarbil.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Gabapentin Enacarbil.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Gabapentin Enacarbil.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Gabapentin Enacarbil.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Gabapentin Enacarbil.Approved, Illicit, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Gabapentin Enacarbil.Approved, Investigational
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Gabapentin Enacarbil.Approved, Illicit, Investigational
GepironeThe risk or severity of adverse effects can be increased when Gepirone is combined with Gabapentin Enacarbil.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Gabapentin Enacarbil.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Gabapentin Enacarbil.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Gabapentin Enacarbil.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Gabapentin Enacarbil.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Gabapentin Enacarbil.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Gabapentin Enacarbil.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Gabapentin Enacarbil.Approved
HydrocodoneGabapentin Enacarbil may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Gabapentin Enacarbil.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Gabapentin Enacarbil.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Gabapentin Enacarbil.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Gabapentin Enacarbil.Approved
IndalpineThe risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Indalpine.Investigational, Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Indiplon is combined with Gabapentin Enacarbil.Investigational
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Gabapentin Enacarbil.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Gabapentin Enacarbil.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Gabapentin Enacarbil.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Gabapentin Enacarbil.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Gabapentin Enacarbil.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Gabapentin Enacarbil.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Gabapentin Enacarbil.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Gabapentin Enacarbil.Approved
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Gabapentin Enacarbil.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Gabapentin Enacarbil.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Gabapentin Enacarbil.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Gabapentin Enacarbil.Approved, Vet Approved
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Gabapentin Enacarbil.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Gabapentin Enacarbil.Illicit
LoprazolamThe risk or severity of adverse effects can be increased when Loprazolam is combined with Gabapentin Enacarbil.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Gabapentin Enacarbil.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Gabapentin Enacarbil.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Gabapentin Enacarbil.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Gabapentin Enacarbil.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Gabapentin Enacarbil.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Gabapentin Enacarbil.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Gabapentin Enacarbil.Approved
MebicarThe risk or severity of adverse effects can be increased when Mebicar is combined with Gabapentin Enacarbil.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Gabapentin Enacarbil.Approved
MedazepamThe risk or severity of adverse effects can be increased when Medazepam is combined with Gabapentin Enacarbil.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Gabapentin Enacarbil.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Gabapentin Enacarbil.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Gabapentin Enacarbil.Approved, Investigational
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Gabapentin Enacarbil.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Gabapentin Enacarbil.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Gabapentin Enacarbil.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Gabapentin Enacarbil.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Gabapentin Enacarbil.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Gabapentin Enacarbil.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Gabapentin Enacarbil.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Gabapentin Enacarbil.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Gabapentin Enacarbil.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Gabapentin Enacarbil.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Gabapentin Enacarbil.Approved
MethotrimeprazineGabapentin Enacarbil may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Gabapentin Enacarbil.Approved, Investigational, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Gabapentin Enacarbil.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Gabapentin Enacarbil.Experimental
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Gabapentin Enacarbil.Approved
MetyrosineGabapentin Enacarbil may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Gabapentin Enacarbil.Approved, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Gabapentin Enacarbil.Approved, Investigational
MirtazapineGabapentin Enacarbil may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Gabapentin Enacarbil.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Gabapentin Enacarbil.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Gabapentin Enacarbil.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Gabapentin Enacarbil.Approved
NefazodoneThe risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Nefazodone.Approved, Withdrawn
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Gabapentin Enacarbil.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Gabapentin Enacarbil.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Norflurane is combined with Gabapentin Enacarbil.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Gabapentin Enacarbil.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Gabapentin Enacarbil.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Gabapentin Enacarbil.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Gabapentin Enacarbil.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Gabapentin Enacarbil.Approved
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Gabapentin Enacarbil.Approved, Illicit
OrphenadrineGabapentin Enacarbil may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Gabapentin Enacarbil.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Gabapentin Enacarbil.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Oxethazaine is combined with Gabapentin Enacarbil.Approved, Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Gabapentin Enacarbil.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Gabapentin Enacarbil.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Gabapentin Enacarbil.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Gabapentin Enacarbil.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Gabapentin Enacarbil.Approved
ParaldehydeGabapentin Enacarbil may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Paroxetine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Penfluridol is combined with Gabapentin Enacarbil.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Gabapentin Enacarbil.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Gabapentin Enacarbil.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Gabapentin Enacarbil.Approved
PerazineThe risk or severity of adverse effects can be increased when Perazine is combined with Gabapentin Enacarbil.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Gabapentin Enacarbil.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Gabapentin Enacarbil.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Gabapentin Enacarbil.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Gabapentin Enacarbil.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Phenibut is combined with Gabapentin Enacarbil.Experimental
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Gabapentin Enacarbil.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Gabapentin Enacarbil.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Gabapentin Enacarbil.Approved
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Gabapentin Enacarbil.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Gabapentin Enacarbil.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Gabapentin Enacarbil.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Gabapentin Enacarbil.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Gabapentin Enacarbil.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Pizotifen is combined with Gabapentin Enacarbil.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Pomalidomide.Approved
PramipexoleGabapentin Enacarbil may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Gabapentin Enacarbil.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Gabapentin Enacarbil.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Gabapentin Enacarbil.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Gabapentin Enacarbil.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Gabapentin Enacarbil.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Gabapentin Enacarbil.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Gabapentin Enacarbil.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Gabapentin Enacarbil.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Gabapentin Enacarbil.Approved
PropanididThe risk or severity of adverse effects can be increased when Propanidid is combined with Gabapentin Enacarbil.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Gabapentin Enacarbil.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Gabapentin Enacarbil.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Gabapentin Enacarbil.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Gabapentin Enacarbil.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Proxibarbal is combined with Gabapentin Enacarbil.Experimental
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Gabapentin Enacarbil.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Gabapentin Enacarbil.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Gabapentin Enacarbil.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Quinisocaine is combined with Gabapentin Enacarbil.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Raclopride is combined with Gabapentin Enacarbil.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Gabapentin Enacarbil.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Gabapentin Enacarbil.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Gabapentin Enacarbil.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Gabapentin Enacarbil.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Gabapentin Enacarbil.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Ritanserin is combined with Gabapentin Enacarbil.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Gabapentin Enacarbil.Vet Approved
RopiniroleGabapentin Enacarbil may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Gabapentin Enacarbil.Approved
RotigotineGabapentin Enacarbil may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Gabapentin Enacarbil.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Gabapentin Enacarbil.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Gabapentin Enacarbil.Approved, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Sepranolone is combined with Gabapentin Enacarbil.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Gabapentin Enacarbil.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Gabapentin Enacarbil.Approved, Vet Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Gabapentin Enacarbil.Approved
StiripentolThe risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Gabapentin Enacarbil.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Gabapentin Enacarbil.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Sultopride is combined with Gabapentin Enacarbil.Experimental
SuvorexantGabapentin Enacarbil may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Tandospirone is combined with Gabapentin Enacarbil.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Gabapentin Enacarbil.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Tasimelteon.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Gabapentin Enacarbil.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Gabapentin Enacarbil.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Gabapentin Enacarbil.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Gabapentin Enacarbil.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Gabapentin Enacarbil.Investigational
ThalidomideGabapentin Enacarbil may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Gabapentin Enacarbil.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Gabapentin Enacarbil.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Gabapentin Enacarbil.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Gabapentin Enacarbil.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Gabapentin Enacarbil.Approved
TiaprideThe risk or severity of adverse effects can be increased when Tiapride is combined with Gabapentin Enacarbil.Approved, Investigational
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Gabapentin Enacarbil.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Gabapentin Enacarbil.Experimental
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Gabapentin Enacarbil.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Gabapentin Enacarbil.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Gabapentin Enacarbil.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Gabapentin Enacarbil.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Gabapentin Enacarbil.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Gabapentin Enacarbil.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Gabapentin Enacarbil.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Gabapentin Enacarbil.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Tricaine methanesulfonate is combined with Gabapentin Enacarbil.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Trichloroethylene is combined with Gabapentin Enacarbil.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Gabapentin Enacarbil.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Trifluperidol is combined with Gabapentin Enacarbil.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Gabapentin Enacarbil.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Gabapentin Enacarbil.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Gabapentin Enacarbil.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Gabapentin Enacarbil.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Veralipride is combined with Gabapentin Enacarbil.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Gabapentin Enacarbil.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Vinyl ether is combined with Gabapentin Enacarbil.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Gabapentin Enacarbil.Approved
XenonThe risk or severity of adverse effects can be increased when Xenon is combined with Gabapentin Enacarbil.Experimental
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Gabapentin Enacarbil.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Gabapentin Enacarbil.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Gabapentin Enacarbil.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Gabapentin Enacarbil.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Gabapentin Enacarbil.Vet Approved
ZolpidemGabapentin Enacarbil may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Gabapentin Enacarbil.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Gabapentin Enacarbil.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Gabapentin Enacarbil.Approved, Investigational
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Gabapentin Enacarbil.Approved, Investigational
Food Interactions
  • No food effects.

References

Synthesis Reference
  1. Cundy KC, Branch R, Chernov-Rogan T, Dias T, Estrada T, Hold K, Koller K, Liu X, Mann A, Panuwat M, Raillard SP, Upadhyay S, Wu QQ, Xiang JN, Yan H, Zerangue N, Zhou CX, Barrett RW, Gallop MA: XP13512 [(+/-)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: I. Design, synthesis, enzymatic conversion to gabapentin, and transport by intestinal solute transporters. J Pharmacol Exp Ther. 2004 Oct;311(1):315-23. Epub 2004 May 14.
General References
  1. Cundy KC, Branch R, Chernov-Rogan T, Dias T, Estrada T, Hold K, Koller K, Liu X, Mann A, Panuwat M, Raillard SP, Upadhyay S, Wu QQ, Xiang JN, Yan H, Zerangue N, Zhou CX, Barrett RW, Gallop MA: XP13512 [(+/-)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: I. Design, synthesis, enzymatic conversion to gabapentin, and transport by intestinal solute transporters. J Pharmacol Exp Ther. 2004 Oct;311(1):315-23. Epub 2004 May 14. [PubMed:15146028]
  2. Bialer M: New antiepileptic drugs that are second generation to existing antiepileptic drugs. Expert Opin Investig Drugs. 2006 Jun;15(6):637-47. [PubMed:16732716]
  3. Cundy KC, Annamalai T, Bu L, De Vera J, Estrela J, Luo W, Shirsat P, Torneros A, Yao F, Zou J, Barrett RW, Gallop MA: XP13512 [(+/-)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: II. Improved oral bioavailability, dose proportionality, and colonic absorption compared with gabapentin in rats and monkeys. J Pharmacol Exp Ther. 2004 Oct;311(1):324-33. Epub 2004 May 14. [PubMed:15146029]
External Links
KEGG Drug
D09539
PubChem Compound
9883933
PubChem Substance
347827805
ChemSpider
8059607
ChEBI
68840
ChEMBL
CHEMBL1628502
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Gabapentin_enacarbil
FDA label
Download (347 KB)
MSDS
Download (30.7 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentHealthy Volunteers1
1CompletedTreatmentPatients With Impaired Renal Function and Haemodialysis1
1CompletedTreatmentRestless Legs Syndrome (RLS)2
1WithdrawnTreatmentRLS1
2Active Not RecruitingTreatmentIrritability / Neurologically Impaired / Pain, Chronic / Signs and Symptoms, Digestive / Sleeplessness1
2CompletedPreventionMigraine Disorders / Migraines1
2CompletedTreatmentAlcohol Use Disorder (AUD)1
2CompletedTreatmentDiabetic Neuropathies1
2CompletedTreatmentPostherpetic Neuralgia2
2CompletedTreatmentRestless Legs Syndrome (RLS)3
2TerminatedTreatmentDiabetic Neuropathies1
2TerminatedTreatmentProstate Cancer1
3CompletedTreatmentRestless Legs Syndrome (RLS)6
4CompletedTreatmentPostoperative pain1
4CompletedTreatmentRestless Legs Syndrome (RLS)2
4Enrolling by InvitationTreatmentRLS1
4Not Yet RecruitingTreatmentFacial Pain / Pain, Acute / Postoperative pain1
4Not Yet RecruitingTreatmentRestless Legs Syndrome (RLS)1
4RecruitingTreatmentAlzheimer's Disease (AD)1
4RecruitingTreatmentRLS1
4RecruitingTreatmentRestless Legs Syndrome (RLS)1
4TerminatedTreatmentRestless Legs Syndrome (RLS)1
Not AvailableRecruitingNot AvailableRestless Legs Syndrome (RLS)1
Not AvailableRecruitingTreatmentPain1
Not AvailableRecruitingTreatmentRestless Legs Syndrome (RLS)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Tablet, extended releaseOral300 mg/1
Tablet, extended releaseOral600 mg/1
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US8048917No2002-11-062022-11-06Us
US8114909No2006-04-112026-04-11Us
US8686034No2005-01-242025-01-24Us
US8795725No2009-06-102029-06-10Us
US8026279No2006-11-102026-11-10Us
US6818787No2002-11-062022-11-06Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)Melting onset of about 64°C.From FDA label.
water solubilitySolubility of 0.5 mg/mL in water From FDA label.
pKapKa 5.0From The Merck Index.
Predicted Properties
PropertyValueSource
Water Solubility0.325 mg/mLALOGPS
logP2.45ALOGPS
logP2.76ChemAxon
logS-3ALOGPS
pKa (Strongest Acidic)4.35ChemAxon
pKa (Strongest Basic)-7.1ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area101.93 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity81.69 m3·mol-1ChemAxon
Polarizability34.38 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as gamma amino acids and derivatives. These are amino acids having a (-NH2) group attached to the gamma carbon atom.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Gamma amino acids and derivatives
Alternative Parents
Dicarboxylic acids and derivatives / Carbamate esters / Organic carbonic acids and derivatives / Carboxylic acid esters / Carboxylic acids / Acetals / Organopnictogen compounds / Organonitrogen compounds / Organic oxides / Hydrocarbon derivatives
show 1 more
Substituents
Gamma amino acid or derivatives / Dicarboxylic acid or derivatives / Carbamic acid ester / Carboxylic acid ester / Carbonic acid derivative / Acetal / Carboxylic acid / Organic nitrogen compound / Organonitrogen compound / Organooxygen compound
show 6 more
Molecular Framework
Aliphatic homomonocyclic compounds
External Descriptors
carbamate ester, monocarboxylic acid, carboxylic ester, acetal (CHEBI:68840)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Voltage-gated calcium channel activity
Specific Function
The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Plays an important role in excitation-...
Gene Name
CACNA2D1
Uniprot ID
P54289
Uniprot Name
Voltage-dependent calcium channel subunit alpha-2/delta-1
Molecular Weight
124566.93 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Voltage-gated calcium channel activity
Specific Function
The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Acts as a regulatory subunit for P/Q-t...
Gene Name
CACNA2D2
Uniprot ID
Q9NY47
Uniprot Name
Voltage-dependent calcium channel subunit alpha-2/delta-2
Molecular Weight
129816.095 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Symporter activity
Specific Function
Acts as an electrogenic sodium (Na(+)) and chloride (Cl-)-dependent sodium-coupled solute transporter, including transport of monocarboxylates (short-chain fatty acids including L-lactate, D-lactat...
Gene Name
SLC5A8
Uniprot ID
Q8N695
Uniprot Name
Sodium-coupled monocarboxylate transporter 1
Molecular Weight
66577.005 Da
References
  1. Cundy KC, Branch R, Chernov-Rogan T, Dias T, Estrada T, Hold K, Koller K, Liu X, Mann A, Panuwat M, Raillard SP, Upadhyay S, Wu QQ, Xiang JN, Yan H, Zerangue N, Zhou CX, Barrett RW, Gallop MA: XP13512 [(+/-)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: I. Design, synthesis, enzymatic conversion to gabapentin, and transport by intestinal solute transporters. J Pharmacol Exp Ther. 2004 Oct;311(1):315-23. Epub 2004 May 14. [PubMed:15146028]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Sodium-dependent multivitamin transmembrane transporter activity
Specific Function
Transports pantothenate, biotin and lipoate in the presence of sodium.
Gene Name
SLC5A6
Uniprot ID
Q9Y289
Uniprot Name
Sodium-dependent multivitamin transporter
Molecular Weight
68641.27 Da
References
  1. Cundy KC, Branch R, Chernov-Rogan T, Dias T, Estrada T, Hold K, Koller K, Liu X, Mann A, Panuwat M, Raillard SP, Upadhyay S, Wu QQ, Xiang JN, Yan H, Zerangue N, Zhou CX, Barrett RW, Gallop MA: XP13512 [(+/-)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: I. Design, synthesis, enzymatic conversion to gabapentin, and transport by intestinal solute transporters. J Pharmacol Exp Ther. 2004 Oct;311(1):315-23. Epub 2004 May 14. [PubMed:15146028]

Drug created on May 02, 2013 15:20 / Updated on December 01, 2017 16:10